Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2023

Open Access 01-12-2023 | Tuberculosis | Research

Tuberculosis prevention, diagnosis, and treatment financial profile during 2006–2021: PART A

Authors: Maryam Meskini, Nahid Madadi, Kamal Ahmadi, Farzam Vaziri, Abolfazl Fateh, Seyed Davar Siadat

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2023

Login to get access

Abstract

Background

Tuberculosis (TB) is a communicable disease that is a major cause of death and one of the leading causes of death worldwide. Currently, there is no analyzed data to examine the financial profile of TB by country, continent, and year; this article analyzed TB prevention, diagnosis, and treatment financial profile during the last two decades.

Methods

Original research, reviews, and governmental databases are analyzed to present the financial profile of TB.

Results

Analyzed data showed Europe (23137.133), Asia (20137.073), and Africa (15237.973) had the most allocated funds (US $ million), and Oceania (236.702), and America (4745.043) had the lowest allocated fund (US $ million) during 2006–2021. Additionally, the allocation of funds (domestic funds, global funds, and grants [excluding global funds]) in different countries and proper planning for TB eradication has caused that in the last two decades, the slope of the confirmed cases and deaths graph line is negative.

Conclusion

The number of confirmed cases and deaths reported globally is decreasing. The trend lines showed that the assigned funds are increasing, indicating that the TB eradication plan can be apprehended soon.
Appendix
Available only for authorised users
Literature
1.
Silva DR, Mello FCQ, Migliori GB. Tuberculosis series 2020. SciELO Brasil; 2020.
2.
Yu Y, Zhang Y, Hu S, Jin D, Chen X, Jin Q et al. Different patterns of cytokines and chemokines combined with IFN-γ production reflect Mycobacterium tuberculosis infection and disease. 2012.
3.
Dhamnetiya D, Patel P, Jha RP, Shri N, Singh M, Bhattacharyya K. Trends in incidence and mortality of tuberculosis in India over past three decades: a joinpoint and age–period–cohort analysis. BMC Pulm Med. 2021;21(1):1–14.CrossRef
4.
Kim S, Kim YK, Lee H, Cho J-E, Kim HY, Uh Y, et al. Interferon gamma mRNA quantitative real-time polymerase chain reaction for the diagnosis of latent tuberculosis: a novel interferon gamma release assay. Diagn Microbiol Infect Dis. 2013;75(1):68–72.CrossRefPubMed
5.
Hidalgo M, Asmat Marrufo P, Lezama Asencio P, Ramos C, Chimoy Tuñoque CA, Zolla G. Evaluation of in vitro susceptibility to sparteine in four strains of Mycobacterium tuberculosis. Revista Peruana de Medicina Experimental y Salud Pública. 2022;39:77–82.CrossRefPubMed
6.
Méda ZC, Huang C-C, Sombié I, Konaté L, Somda PK, Djibougou AD et al. Tuberculosis in developing countries: conditions for successful use of a decentralized approach in a rural health district. Pan Afr Med J. 2014;17.
7.
Narasimhan P, Wood J, MacIntyre CR, Mathai D. Risk factors for tuberculosis. Pulmonary medicine. 2013;2013.
8.
Kirenga BJ, Ssengooba W, Muwonge C, Nakiyingi L, Kyaligonza S, Kasozi S, et al. Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: implications for tuberculosis control. BMC Public Health. 2015;15(1):1–7.CrossRef
9.
MEYSAMI A, SALEHI M, Sargolzaei N. Trend of smear positive pulmonary tuberculosis in Sistan and Baluchestan Province (2005–2008). 2010.
10.
Daniel T. Historical review. The history of tuberculosis. Respiratory Med. 2006;100(11):1862–70.CrossRef
11.
Alashavi H, Daher M, Chorgoliani D, Saflo M, Zeidan M, Huseyinibrahim F et al. Descriptive epidemiology of the Tuberculosis Service Delivery Project beneficiaries in Northwest Syria: 2019–2020. Front Public Health. 2021:942.
12.
Bahizi G, Majwala RK, Kisaka S, Nyombi A, Musisi K, Kwesiga B, et al. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014–2018. Antimicrob Resist Infect Control. 2021;10(1):1–9.CrossRef
13.
Asres A, Jerene D, Deressa W. Pre-and post-diagnosis costs of tuberculosis to patients on directly observed treatment short course in districts of southwestern Ethiopia: a longitudinal study. J Health Popul Nutr. 2018;37(1):1–11.CrossRef
14.
Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low-and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763–75.CrossRefPubMedPubMedCentral
15.
WHO G. Global tuberculosis report 2020. Glob Tuberc Rep. 2020.
16.
Goodchild M, Sahu S, Wares F, Dewan P, Shukla R, Chauhan L, et al. A cost-benefit analysis of scaling up tuberculosis control in India. Int J Tuberc Lung Dis. 2011;15(3):358–62.PubMed
17.
Fukunaga R, Glaziou P, Harris JB, Date A, Floyd K, Kasaeva T. Epidemiology of tuberculosis and progress toward meeting global targets—worldwide, 2019. Morb Mortal Wkly Rep. 2021;70(12):427.CrossRef
18.
Dirlikov E, Raviglione M, Scano F. Global tuberculosis control: toward the 2015 targets and beyond. Ann Intern Med. 2015;163(1):52–8.CrossRefPubMed
19.
Floyd K, Glaziou P, Houben R, Sumner T, White R, Raviglione M. Global tuberculosis targets and milestones set for 2016–2035: definition and rationale. Int J Tuberc Lung Dis. 2018;22(7):723–30.CrossRefPubMedPubMedCentral
20.
Organization WH. Tuberculosis control: report of a meeting of national programme managers and partners, New Delhi, India, 10–14 November 2014. World Health Organization; 2015.
21.
Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets. The Lancet Global Health. 2013;1(2):e105–e15.CrossRefPubMed
22.
Floyd K, Pantoja A, Dye C. Financing tuberculosis control: the role of a global financial monitoring system. Bull World Health Organ. 2007;85:334–40.CrossRefPubMedPubMedCentral
23.
Su Y, Baena IG, Harle AC, Crosby SW, Micah AE, Siroka A, et al. Tracking total spending on tuberculosis by source and function in 135 low-income and middle-income countries, 2000–17: a financial modelling study. Lancet Infect Dis. 2020;20(8):929–42.CrossRefPubMedPubMedCentral
Metadata
Title
Tuberculosis prevention, diagnosis, and treatment financial profile during 2006–2021: PART A
Authors
Maryam Meskini
Nahid Madadi
Kamal Ahmadi
Farzam Vaziri
Abolfazl Fateh
Seyed Davar Siadat
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2023
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-023-00479-z

Other articles of this Issue 1/2023

Cost Effectiveness and Resource Allocation 1/2023 Go to the issue

Research

The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?

Research

Impact of a diabetes pay-for-performance program on nonincentivized mental disorders: a panel study based on claims database analysis

Review

Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer

Research

Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

Research

COVID-19 versus applied infection control policies in a Major Transplant Center in Iran

Research

Economic evaluations of non-communicable diseases conducted in Sub-Saharan Africa: a critical review of data sources